EA3163
|
ECOG-ACRIN
|
Phase II Randomized Trial of Neo-Adjuvant Chemotherapy followed by Surgery and Post-Operative Radiation versus Surgery and Post-Operative Radiation for Organ Preservation of T3 and T4a Nasal and Paranasal Sinus Squamous Cell Carcinoma (NPNSCC)
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
EA3191
|
ECOG-ACRIN
|
A Phase II Randomized Trial of Adjuvant Therapy with Pembrolizumab after Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma with High Risk Features
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
EA3202
|
ECOG-ACRIN
|
A Phase II/III Trial of Chemotherapy + Cetuximab vs Chemotherapy + Bevacizumab vs Atezolizumab + Bevacizumab Following Progression on Immune Checkpoint Inhibition in Recurrent/Metastatic Head and Neck Cancers
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
EA3211
|
ECOG-ACRIN
|
Phase III Randomized Trial of Immunotherapy with or without Consolidative Radiotherapy for Oligometastatic Head and Neck Squamous Cell Carcinoma
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
EA3231
|
ECOG-ACRIN
|
A Randomized Phase III Study of BRAF-Targeted Therapy vs Cabozantinib in RAI-Refractory Differentiated Thyroid Cancer with BRAF V600Em
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
EA4151
|
ECOG-ACRIN
|
A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
EA4181
|
ECOG-ACRIN
|
A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients ≤ 70 years old with Untreated Mantle Cell Lymphoma
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
EA5123
|
ECOG-ACRIN
|
Role of Early 18F-FDG-PET/CT Scan in Predicting Mediastinal Downstaging with Neoadjuvant Chemotherapy in Resectable Stage III A NSCLC
|
Adult CIRB - Late Phase Emphasis
|
Completed
|
|
EA5142
|
ECOG-ACRIN
|
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
EA5152
|
ECOG-ACRIN
|
A Randomized Phase II Trial of Nivolumab, Cabozantinib Plus Nivolumab, and Cabozantinib Plus Nivolumab Plus Ipilimumab in Patients with Previously Treated Non-Squamous NSCLC
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|